Log In
BCIQ
Print this Print this
 

BluePrint

  Manage Alerts
Collapse Summary General Information
Company Agendia N.V.
DescriptionMolecular subtyping test for classifying breast cancer into basal-type, luminal-type and HER2-type
Molecular Target Epidermal growth factor receptor 2 (HER2) (EGFR2) (ErbB2) (neu)
Mechanism of ActionDiagnostic
Therapeutic ModalityDiagnostics
Latest Stage of DevelopmentMarketed
Standard IndicationCancer, Diagnostic
Indication DetailsClassify breast cancer into basal-type, luminal-type and HER2-type
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today